Conference Presentation, Panel
Accelerating a Healthier Future Through AI | Global Conference 2025
- Chronic disease demographics and longevity trends are predicted to worsen workforce shortages, necessitating technology solutions while the American Medical Association observes physician AI adoption doubling from 38% to 66% over the last two years.
- Rapid uptake of ambient dictation, back-end scheduling, and clinical applications is expected to reduce administrative overhead, improve record accuracy, increase patient satisfaction via maintained eye contact, and alleviate prior authorization struggles for small practices.
- UCLA Health plans to deploy AI in radiology, cardiology, neurology, and neurosciences to enhance data assimilation and predictive modeling, including identifying risks for end-stage renal disease and anesthetic complications.
- Tempus intends to develop precision medicine platforms and natural language agents that interpret genetic sequencing, treatment guidelines, and trial availability, utilizing multimodal data from blood work, wearables, and biometrics to predict disease onset and therapy needs.
- The ambient scribe market is expected to consolidate quickly through strategic partnerships among large electronic health record vendors, while integrated API systems for billing and insurance may accelerate faster than anticipated.
- Wearables are projected to establish individual biometric baselines for algorithmic care, improve adherence through minute-by-minute interactions, and enable patient navigation systems to utilize machine learning for routing to appropriate specialists.
- An ecosystem of "agent interfaces" sitting atop best-of-breed services is expected to emerge within five to ten years, alongside portable, personalized AI models that allow patients to act as CEOs of their health journeys and own their consolidated data.
- Automation is anticipated to improve healthcare reliability from its current 80%, with automated pharmaceutical fulfillment enabling drug delivery within eight hours, though human oversight will remain mandatory for diagnostics and safety.
- AI is expected to be disruptive in oncology by enhancing diagnostic tools like minimal residual disease testing and integrating genomic information to improve clinical trial design and pharmacogenetic screening for cardiovascular risks.
- Regulatory frameworks are not expected to catch up to technological deployment in the near future, though systems may evolve to be risk-dependent similar to automated driving levels while maintaining requirements for human-in-the-loop processes.
- Labor concerns regarding job displacement may lead to contract language ensuring technology does not eliminate positions, even as experts predict AI will upgrade rather than replace doctors, allowing focus on critical cases and increased patient volume.
- Large academic medical centers are expected to increasingly appoint physician-leaders to standardize AI investments, while patient trust in tools is linked to transparency regarding usage and quality improvements.
- Interoperability will become critical to support digital tools amidst fragmented data silos, potentially reducing test duplication and enabling a new era of citizen science through cross-platform collaboration.
- Patient adoption of tools like MyChart is currently estimated at 60%, with future innovations expected to improve call center efficiency and appointment sorting while leveraging large population data for economic research and personalized trial predictions.